Furthermore, our studies in GEM models, patient-derived organoids, and patient samples showed that PTEN defects are associated with a better response to Aurora A inhibition in advanced prostate cancer by inducing CHD1 protein stabilization (26). This evidence concerns the gene CHD1 and prostate cancer.